| Name | Title | Contact Details |
|---|
Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing technology applications to patients.
Codex DNA is home to Gibson Assembly, and pioneering synthetic DNA/gene synthesis hardware, including the BioXp, the world’s first DNA printer. Our mission is to empower scientific researchers in both academic and commercial settings with the materials...
Cellular Technology is a Beachwood, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Radient Pharmaceuticals Corporation is a Tustin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus.